COPD Management Guidelines

Diagnosis and Assessment

Spirometry is mandatory for diagnosis, confirming airflow limitation with post-bronchodilator FEV1/FVC ratio <0.7, and severity classification is based on FEV1 percentage predicted: mild (60-80%), moderate (40-59%), severe (<40%) 1
Assessment must include symptom evaluation, exacerbation history, and blood gas analysis in severe disease 1

The American Thoracic Society recommends starting with a single bronchodilator: short-acting β2-agonist OR short-acting anticholinergic as needed for Group A patients (Low Symptoms, Low Exacerbation Risk) 1
For Group B patients (High Symptoms, Low Exacerbation Risk), initiate long-acting bronchodilator monotherapy: LAMA or LABA, and escalate to LAMA + LABA combination if inadequate response 1
For Group C patients (Low Symptoms, High Exacerbation Risk), start with LAMA monotherapy, and for Group D patients (High Symptoms, High Exacerbation Risk), begin with LAMA + LABA combination therapy 1
Add inhaled corticosteroid (ICS) to LABA/LAMA only if blood eosinophils are elevated AND/OR concomitant asthma is present 1

Smoking cessation is mandatory at all disease stages, and active cessation programs with nicotine replacement therapy achieve higher sustained quit rates 1, 2, 3
Pulmonary rehabilitation is recommended for all symptomatic patients, improving exercise performance, reducing breathlessness, and decreasing hospitalizations 1, 2
Influenza vaccination is recommended annually for all COPD patients, and pneumococcal vaccinations (PCV13 and PPSV23) are recommended for patients ≥65 years and younger patients with significant comorbidities 1

Long-term oxygen therapy (LTOT) is indicated and prolongs survival when PaO2 ≤55 mmHg or SaO2 ≤88% (confirmed twice over 3 weeks), or PaO2 55-60 mmHg or SaO2 88% WITH pulmonary hypertension, peripheral edema, or polycythemia 1

Treat exacerbations promptly with increased bronchodilator dose/frequency, antibiotics if ≥2 of the following: increased breathlessness, increased sputum volume, purulent sputum, and oral corticosteroids (30mg prednisolone daily for 7 days) in appropriate cases 1, 4

Non-invasive ventilation (NIV) is recommended for pronounced daytime hypercapnia with recent hospitalization, and lung volume reduction surgery (surgical or bronchoscopic) is recommended for selected patients with heterogeneous/homogeneous emphysema and significant hyperinflation 1
Lung transplantation is recommended for very severe COPD in selected candidates 1

Do not use theophyllines routinely due to limited value with potential toxicity, and avoid prophylactic oral corticosteroids for exacerbation prevention 2
Do not prescribe ICS without specific indications (eosinophilia or asthma), and verify inhaler technique regularly to ensure proper use 2
Do not rely on short-burst oxygen for breathlessness without documented hypoxemia, as evidence is lacking 2, 3

Regular spirometry is recommended to detect rapid decline, and reassess inhaler technique and treatment adherence at each visit 1, 4
Screen for and manage comorbidities (cardiovascular disease, depression, osteoporosis) to improve overall patient outcomes 4